Meetings / Live CME


Collaborate with your peers and master the latest knowledge in your cardiovascular specialty.


2017 AHA Conferences

International Stroke Conference
Feb. 22–24 | Houston, Texas
EPI|Lifestyle
March 7–10 | Portland, Ore.
QCOR
April 2–3 | Arlington, Va.
ATVB|PVD
May 4–6 | Minneapolis, Minn.
BCVS
July 10–13 | Portland, Ore.
Council on Hypertension
September 14–17 | San Francisco, Calif.
Scientific Sessions
November 11–15 | Anaheim, Calif.

Add these dates to your calendar

Conference Science NewsView All

Science News Scientific Sessions 2016 ARCHIVE
11/11/2016 | Science News coverage of selected presentations and interviews from AHA's Scientific Sessions 2016. Nov. 12-16, 2016 in New Orleans, La.
Archive: Science News - 2016 Hypertension Scientific Sessions
09/14/2016 | Science News analysis, interviews and presentations from the Council on Hypertension Scientific Sessions 2016 conference in Orlando, Flor...
Science News for BCVS 2016
07/18/2016 | Science News, presentations, and video interviews from the Basic Cardiovascular Science 2016 Scientific Sessions in Phoenix, Arizona
Science News from ATVB|PVD 2016
05/05/2016 | Science News from ATVB 2016 Scientific Sessions: presentation slides, abstracts, exclusive video interviews, and more.
Science News (EPI Lifestyle) 2016 Archive
03/01/2016 | Science News from Epidemiology and Prevention/Lifestyle 2016 Scientific Sessions

Key Highlights from Scientific Sessions 2016



Top Science Stories from Scientific Sessions 2016

Steve Houser, MD, president, American Heart Association, Frank Sellke, MD, and Eric Peterson, MD review the big science stories from Scientific Sessions 2016 in New Orleans.


Inhibition of PCSK9 Synthesis via RNA Interference: 90 Day Data From Orion-1-a Multi-centre Phase-2 Randomized Controlled Trial
Kausik K Ray | Imperial College of London, London, United Kingdom

RESULTS: At 180 days, inhibiting PCSK9 synthesis using RNA interference safely reduced LDL-C.


Manesh R. Patel

Effects of Ticagrelor Compared With Clopidogrel in Patients With Peripheral Artery Disease (EUCLID)
Manesh R Patel | Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

RESULTS: PAD patients did not gain more benefit from long-term ticagrelor compared to clopidogrel in preventing cardiovascular death, heart attack, or ischemic stroke. The primary endpoint was not met.

AHA Guidelines on-the-go! Download today on the App Store or Get it on Google Play
International Stroke Conference 2017

February 22–24, 2017
Houston, Texas

EPI-Lifestyle 2016 

March 7–10, 2017
Portland, Oregon

QCOR 2017
 

April 2–3, 2017
Arlington, Virginia